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Clinics and pathology 
Disease 
Rhabdomyosarcomas, the most common pediatric soft 
tissue sarcomas, are tumours related to the skeletal 
muscle lineage. The 2 major subtypes are alveolar 
rhabdomyosarcoma (ARMS) and embryonal 
rhabdomyosarcoma (ERMS). Other subtypes are 
botryoid, spindle cell, anaplastic, pleomorphic, and 
undifferentiated RMS. 
Note 
Most ARMS cases are characterised by either a 
t(2;13)(q35;q14), resulting in a PAX3/FOXO1 hybrid 
gene, or a t(1;13)(p36;q14) resulting in a 
PAX7/FOXO1 hybrid gene. Most ERMS are 
characterized by chromosome gains and a loss of 
heterozygocity in 11p15. 
Epidemiology 
Three cases of RMS with t(11;22)(q24;q12) have been 
described to date, including a two-years-old girl with a 
mixed embryonal and alveolar RMS, who died 14 
months after diagnosis, a 4.5-year-old girl, also with a 
mixed embryonal and alveolar RMS, who was alive 
and well 9 months after diagnosis (Sorensen et al., 
1993; Thorner et al., 1996). 
Genetics 
Note 
A t(2;13) hybrid transcript was excluded in the two 
cases described by Thorner et al., 1996. In the 4.5-year-
old girl case, a highly abnormal karyotype was found, 
with 85 to 200 chromosomes per mitosis, and MDM2 
was amplified more than a hundred times. 
 
 





From N-term to C-term: a 5' ETS domain, a Fli-1-
specific transcriptional activation domain, and a 3' ETS 
transcriptional activation domain. Member of ETS 
transcription factor gene family. FLI1 binds to DNA in 





From N-term to C-term: a transactivation domain 
(TAD) containing multiple degenerate hexapeptide 
repeats, 3 arginine/glycine rich domains (RGG 
regions), a RNA recognition motif, and a RanBP2 type 
Zinc finger. Role in transcriptional regulation for 
specific genes and in mRNA splicing. 




5' EWSR1 - 3' FLI1. EWSR1 exon 7 is fused in frame 
to FLI1 exon 6. 
Fusion Protein 
Description 
Fusion of the N terminal transactivation domain of 
EWSR1 to the ETS type DNA binding domain of FLI1. 
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